StockNews.AI
HUMA
StockNews.AI
208 days

HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

1. Humacyte facing class action lawsuit for misleading statements. 2. Allegations include quality compliance issues in manufacturing. 3. FDA review delays threaten approval of ATEV for vascular trauma.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Legal challenges may lead to decreased investor confidence, impacting stock performance. Past examples like other biotech litigation show significant price drops.

How important is it?

Lawsuit details directly affect shareholder confidence and stock trajectory.

Why Short Term?

Immediate investor reactions likely affect stock price shortly. Similar cases have shown quick market responses to legal troubles.

Related Companies

HUMA
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Humacyte, Inc. (NASDAQ: HUMA) on behalf of long-term stockholders following a class action complaint that was filed against Humacyte on November 18, 2024 with a Class Period from May 10, 2024 to October 17, 2024. Our investigation concerns whether the board of directors of Humacyte have breached their fiduciary duties to the company. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors: (1) that the Company's Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) that the FDA's review of the BLA would be delayed while Humacyte remediated these deficiencies; and (3) that, as a result, there was a substantial risk to FDA approval of ATEV for vascular trauma; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you are a long-term stockholder of Humacyte, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News